

Express Mail No.: EM 490 490 717 US

**PENNIE & EDMONDS** LLP  
COUNSELLORS AT LAW  
1155 Avenue of the Americas  
New York, N.Y. 10036-2711  
(212) 790-9090



ATTORNEY DOCKET NO. 6923-071-999

Date April 30, 1998

Assistant Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Peter Palese et al.

Executed on:

Title of Invention: RECOMBINANT INFLUENZA VIRUSES EXPRESSING TUMOR-ASSOCIATED ANTIGENS AS ANTITUMOR AGENTS

**PATENT APPLICATION FEE VALUE**

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	19	-20		\$22.00 each	
Independent	1	-3		\$82.00 each	
Minimum Fee					790.00
Multiple Dependency Fee If Applicable (\$270.00)					
Total					
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					-
Total Filing Fee					\$ 790.00

- ☒ Priority of application no. 60/045,176 filed on April 30, 1997 claimed under 35 U.S.C. § 119(e).  
☐ The certified copy of the priority application has been filed in application no. filed .  
☐ Amend the specification by inserting before the first line the following sentence; This is a continuation-in-part of application no. filed .

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

*Laura A. Coruzzi*  
\_\_\_\_\_  
Laura A. Coruzzi  
PENNIE & EDMONDS LLP

30,742  
(Reg. No.)

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

Please type a plus (+) inside this box → ☐

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	6923-071-999	Total Pages	
First Named Inventor or Application Identifier			
Adolfo García-Sastre et al.			
Express Mail Label No.	EM 490 490 717 US		

**APPLICATION ELEMENTS**  
See MPEP chapter 600 concerning utility patent application contents.

**ADDRESS TO:** Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ Fee Transmittal Form  
*Submit an original, and a duplicate for fee processing*
2. ☒ Specification [Total Pages 29]  
*(preferred arrangement set forth below)*
  - Descriptive title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings *(if filed)*
  - Detailed Description of the Invention *(including drawings, if filed)*
  - Claim(s)
  - Abstract of the Disclosure
3. ☐ Drawing(s) *(35 USC 113)* [Total Sheets 4]
4. ☒ Oath or Declaration (Unexecuted) [Total Sheets 2]
  - a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))  
*(for continuation/divisional with Box 17 completed)*  
**[Note Box 5 below]**
  - i. ☐ **DELETION OF INVENTORS(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
5. ☐ Incorporation By Reference *(useable if Box 4b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program *(Appendix)*
7. ☐ Nucleotide and/or Amino Acid Sequence Submission  
*(if applicable, all necessary)*
  - a. ☐ Computer Readable Copy
  - b. ☐ Paper Copy (identical to computer copy)
  - c. ☐ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
*(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☐ Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*
14. ☐ Small Entity ☐ Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)  
*(if foreign priority is claimed)*
16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:  
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: filed .

**18. CORRESPONDENCE ADDRESS**

☒ Customer Number or Bar Code Label 20583 or ☐ Correspondence address below  
*(Insert Customer No. or Attach bar code label here)*

NAME					
ADDRESS					
CITY		STATE		ZIP CODE	
COUNTRY		TELEPHONE		FAX	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



EXPRESS MAIL # EM 490 490 717 US

RECOMBINANT INFLUENZA VIRUSES EXPRESSING  
TUMOR-ASSOCIATED ANTIGENS AS ANTITUMOR AGENTS

5

This application claims priority to U.S.  
provisional application Serial No. 60/045,176, filed April  
30, 1997, incorporated by reference herein, in its entirety.  
The work reflected in this application was supported, in  
10 part, by a grant from the National Institutes of Health, and  
the Government may have certain rights in the invention.

1. INTRODUCTION

The present invention relates to the engineering of  
15 recombinant influenza viruses that express tumor-associated  
antigens. Expression of tumor-associated antigens by these  
viruses can be achieved by engineering specific epitopes into  
influenza virus proteins, or by engineering viral genes that  
encode a viral protein and the specific antigen as  
20 independent polypeptides. Tumor-bearing patients can be  
immunized with the recombinant influenza viruses alone, or in  
combination with another treatment, to induce an immune  
response that leads to tumor reduction. The recombinant  
viruses can also be used to vaccinate high risk tumor-free  
25 patients to prevent tumor formation in vivo.

2. BACKGROUND OF THE INVENTION

A number of immunotherapeutic approaches proposed  
for the treatment of tumors have had limited success. For  
30 example, the use of exogenous antibodies or immunotoxins  
specific for tumor associated antigens (TAAs) has been  
attempted for the targeted killing of tumor cells. However,  
successful treatment has been hampered, in part, by the  
relative inaccessibility of the tumor cells to the  
35 circulating, exogenously administered antibodies.

Other approaches have been designed to elicit a host immune response against the tumor cells. Indeed, there is strong evidence suggesting that the stimulation of a potent and specific T-cell response against tumor cells will result in tumor reduction. However, although most cancer cells express tumor associated antigens (TAAs), the presence of a tumor usually does not result in the induction of tumor-specific immunity. Attempts to increase the poor immunogenicity of tumor cells comprise most of the history of cancer immunotherapy. These efforts have included physical modification of the tumor cells (including  $\gamma$ -irradiation), the inoculation of mixtures of tumor cells and pathogens (viruses, bacteria and bacterial extracts) and more recently, gene-modification of the tumor cells with a variety of immunomodulatory molecules.

In the case of vaccination in the treatment and/or prevention of cancer, a potentially effective strategy for eliciting vigorous immune responses against TAAs may involve the insertion of the cloned genes encoding TAAs into recombinant viruses (reviewed in Restifo, 1996, Curr. Opin. Immunol. 8:658-663). A number of recombinant expression vectors have been shown to be useful in the prevention, and in some cases in the treatment, of tumors in experimental animals including poxviruses (vaccinia (Hodge, et al., 1995, Int. J. Cancer 63:231-237)), fowlpox (Wang, et al., 1995, J. Immunol. 154:4685-4692) and canary pox (Plotkin, et al., 1995, Dev. Biol. Stand. 84:165-170)); adenoviruses (Chen, et al., 1996, J. Immunol. 156:224-231; Randrianarison-Jewtoukoff and Perricaudet, 1995, Biologicals 23:145-157); polioviruses (Ansardi, et al., 1994, Cancer Res. 54:6359-6364); Sindbis viruses (Johanning, et al., 1995, Nucleic Acids Res. 23:1495-1501) and non-viral vectors including plasmid DNA administered by injection (Conry, et al., 1995, Gene Ther. 2:59-65) and by "gene gun" (Irvine, et al., 1996, J. Immunol. 156:238-245).

However, the foregoing systems have limitations which restrict their use in humans. For example, pre-

existing immunity to vaccinia or adenovirus precludes their use as vaccinating strains. Moreover, the immune response induced by vaccinia or adenovirus precludes the use of the same virus for a second immunization or boost. In addition, 5 the pathogenicity associated with some virus vectors, e.g., adenoviruses, also severely limit their use in vaccine formulations for human patients. Thus, there is a need for the continued exploration of new vector systems for use in cancer vaccines.

10

### 3. SUMMARY OF THE INVENTION

The invention relates to recombinant influenza viruses that express TAAs, and their use to "immunize" tumor-bearing hosts in order to generate an immune response that 15 leads to tumor regression. Alternatively, tumor-free subjects who have a predisposition to develop tumors can be immunized or vaccinated with the recombinant influenza viruses of the invention to prevent tumor formation.

Expression of TAAs by these viruses can be achieved 20 by engineering specific TAA epitopes into the influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. The methods of the present invention permit the generation of stable recombinant viruses expressing foreign epitopes and/or 25 polypeptides.

Reverse genetics techniques to engineer influenza viruses are described. Immunization of tumor-bearing patients with such viruses alone, or in combination with another treatment, to induce an immune response that leads to 30 tumor reduction is also described. For example, the recombinant influenza viruses of the invention can be used to immunize or "vaccinate" a tumor-bearing host in order to generate an immune response against tumor cells. The antitumor immune response can be enhanced by a subsequent 35 "booster" immunization using a subunit vaccine preparation containing the appropriate TAA, a different viral vector (e.g., a pox virus based vector) that expresses the TAA, or

TAA expressed by an influenza recombinant engineered using a serotype that differs from the initial inoculant. The immunization protocol may be used alone or in conjunction with surgical, radiation or chemotherapeutic regimens.

- 5 Alternatively, tumor-free hosts can be similarly vaccinated to prevent tumor formation in vivo.

- The invention is based, in part, on the surprising discovery that the recombinant influenza viruses of the invention induce a potent and specific cell-mediated immune response directed against the tumor cells resulting in tumor reduction. The invention is also based, in part, on the recognition that non-transmissible attenuated strains of influenza virus could be used to engineer vaccines for use in humans. Moreover, since influenza viruses change their antigenic determinants very quickly, different viral strains can be selected and engineered for use to avoid the presence of pre-existing immunity against the virus in patients. Strain variability permits the construction of a vast repertoire of vaccine formulations, and obviates the problems of host resistance.
- 10  
15  
20

- The invention is illustrated by way of working examples which demonstrate the invention in a murine model. Strikingly, mice immunized with a recombinant influenza A virus vector, and boosted with a vaccinia virus vector expressing the same antigen were able to generate high levels of CTLs against the expressed antigen. Treatment with the recombinant influenza virus vectors mediated regression of an experimental established murine cancer.
- 25

30 3.1. ABBREVIATIONS

- CTL, cytotoxic lymphocyte  
 $\beta$ -gal,  $\beta$ -galactosidase  
HA, hemagglutinin  
IRES, internal ribosomal entry site  
35 MOI, multiplicity of infection  
NA, neuraminidase  
PFU, plaque forming units

TAA, tumor-associated antigen

#### 4. DESCRIPTION OF THE FIGURES

Figure 1. Schematic representation of the recombinant genes of the transfectant influenza viruses expressing the CD8+ T-cell  $\beta$ -gal epitope TPHPARIGL.

A. MINIGAL recombinant gene. The  $\beta$ -gal epitope is expressed downstream of a leader peptide (characters in italics) as an independent polypeptide from a bicistronic NA gene. Expression of the viral NA protein in this gene is achieved via internal initiation of translation mediated by an IRES element derived from the BiP mRNA (Garcia-Sastre, *et al.*, 1994, J. Virol. 68:6254-6261).

B. NAGAL. The  $\beta$ -gal epitope is expressed as part of the amino acid sequence of the NA protein.

C. BHAGAL. The  $\beta$ -gal epitope is expressed as part of the amino acid sequence of the HA protein.

The NA and HA open reading frames (ORF) are indicated. Black boxes represent noncoding regions in the represented genes.

Figure 2. Specific recognition of transfectant influenza A viruses-infected cells by a  $\beta$ -gal-specific CTL clone. Five  $\times 10^5$  CT26.WT cells/well (24 well plate) were incubated in RPMI, 0.1 % BSA, 30mM HEPES at pH 6.8, and they were infected with the influenza viruses shown at an MOI of 5 for 3 hours. Specific CTLs against the  $\beta$ -gal epitope TPHPARIGL were then added at an E:T ratio of 1. After 24 hours of coincubation cell supernatants were harvested and assayed for GM-CSF. Results from two independent experiments are represented. WT, influenza A/WSN/33 wild-type virus.

Fig. 3. Specific cytolytic responses induced in mice by transfectant influenza A viruses expressing the  $\beta$ -gal epitope TPHPARIGL. To evaluate the function of transfectant influenza A viruses in the priming of  $\beta$ -gal-specific cytotoxic responses in vivo, two mice/group were infected with the influenza A virus shown on the abscissa. Three weeks latter, splenocytes from immunized mice were cultured

in the presence of the L<sup>d</sup>-restricted  $\beta$ -gal<sub>876-884</sub> peptide for 6 days then tested in a microcytotoxicity assay against CT26.WT, CT26.CL25 or CT26.WT cells loaded with the  $\beta$ -gal<sub>876-884</sub> peptide, at the indicated E:T ratios. Experiment was performed two additional times with similar results.

Fig. 4. Transfectant influenza A viruses mediate treatment of pulmonary metastases established for three days. Mice were inoculated intravenously with  $5 \times 10^6$  CT26.CL25 tumor cells, then vaccinated three-days later with  $10^6$  pfu of the transfectant influenza A virus shown. Twelve hours after the therapeutic immunization, mice were given 100,000 Cetus units of rIL-2 bid for 3 days. The lungs of treated mice were evaluated in a coded, blinded manner for pulmonary metastases 12 days after the tumor inoculation. The number of pulmonary metastases that were enumerated after two independent experiments are shown for individual mice.

#### 5. DETAILED DESCRIPTION OF THE INVENTION

The engineering of recombinant influenza viruses expressing TAAs, and their use as immunogenic compositions or vaccines to induce tumor regression in mammals, including humans, is described. One drawback to the use of viruses such as vaccinia for constructing recombinant or chimeric viruses for use in vaccines is the lack of variation in its major epitopes. This lack of variability in the viral strains places strict limitations on the repeated use of chimeric vaccinia virus, in that a first vaccination will generate host resistance to the strain so that the same virus cannot infect the host in a second inoculation. Inoculation of a resistant individual with chimeric vaccinia virus will, therefore, not induce immune stimulation. The considerable advantage of using influenza virus, a negative-strand RNA virus, for vaccination, is that it demonstrates a wide variability of its major epitopes. Thousands of variants of influenza virus have been identified, each strain evolving by antigenic drift.



00070639 013099  
00000000 00000000

"Reverse genetics" techniques are used to construct recombinant and/or chimeric influenza virus templates engineered to direct the expression of heterologous gene products. When combined with purified viral RNA-directed RNA polymerase, these virus templates are infectious, replicate in hosts, and their heterologous gene is expressed and packaged by the resulting recombinant influenza viruses (For a description of the reverse genetics approach see Palese et al., U.S. Patent No. 5,166,057 and Palese, WO93/21306, each of which is incorporated by reference herein in its entirety). The expression products and/or chimeric virions obtained can be used in vaccine formulations, and the strain variability of the influenza virus permits construction of a vast repertoire of vaccine formulations and obviates the problem of host resistance. Furthermore, influenza virus stimulates a vigorous cytotoxic T cell response. Hence, the presentation of foreign epitopes in an influenza virus background can further induce secretory immunity and cell-mediated immunity.

20

#### 5.1. CONSTRUCTION OF THE RECOMBINANT INFLUENZA A VIRUS

In accordance with the invention, recombinant influenza viruses are engineered to express tumor-associated antigens (TAAs), including, but not limited to, the TAAs set forth in Table 1.

30

35

---

TABLE 1

Human tumor antigens recognized by T cells (Robbins and Kawakami, 1996, Curr. Opin. Immunol. 8:628-636)

5 Melanocyte lineage proteins

gp100

MART-1/MelanA

TRP-1 (gp75)

Tyrosinase

10 Tumor-specific, widely shared antigens

MAGE-1

MAGE-3

BAGE

GAGE-1, -2

15 N-acetylglucosaminyltransferase-V

p15

Tumor-specific, mutated antigens

$\beta$ -catenin

MUM-1

20 CDK4

Nonmelanoma antigens

HER-2/neu (breast and ovarian carcinoma)

Human papillomavirus-E6, E7 (cervical carcinoma)

MUC-1 (breast, ovarian and pancreatic carcinoma)

---

25

Indeed, antigens which are identified in the future as TAAs are included within the scope of the invention for the construction of recombinant influenza viruses by the techniques described herein. The selection of the TAA or its

30 epitope will depend upon the tumor type to be treated.

The use of reverse genetics to genetically engineer influenza viruses, including attenuated influenza viruses, and methods for their production, are described in Palese et al. (U.S. Patent No. 5,166,057) and Palese (WO93/21306).

35 Such reverse genetics techniques can be utilized to engineer a mutation, including but not limited to an insertion,

deletion, or substitution of an amino acid residue(s), an antigen(s), or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus. Alternatively, the virus  
5 can be engineered to express the TAA as an independent polypeptide.

The reverse genetics technique involves the preparation of synthetic recombinant viral RNAs that contain the non-coding regions of the negative strand virus which are  
10 essential for the recognition of viral RNA by viral polymerases and for the packaging into mature virions. The recombinant RNAs are synthesized from a recombinant DNA template and reconstituted in vitro with purified viral polymerase and nucleoprotein complex to form recombinant  
15 ribonucleoproteins (RNPs) which can be used to transfect cells.

Preferably, the viral polymerase proteins are present during in vitro transcription of the synthetic RNAs prior to transfection. The synthetic recombinant RNPs can be  
20 rescued into infectious virus particles. The foregoing techniques are described in Palese et al., U.S. Patent No. 5,166,057, and in Enami and Palese, 1991, J. Virol. 65:2711-2713, each of which is incorporated by reference herein in its entirety.

Such reverse genetics techniques can be used to  
25 insert a TAA or an epitope of TAA into an influenza virus protein so that a chimeric protein is expressed by the virus. While any of the influenza viral proteins may be engineered in this way, the influenza HA or NA proteins are preferred  
30 when it is desired to engineer the expression of the TAA or epitope on the surface of the recombinant influenza virus.

Alternatively, viral genes can be engineered to encode a viral protein and the specific TAA as independent polypeptides. To this end, reverse genetics can  
35 advantageously be used to engineer a bicistronic RNA segment as described in U.S. Patent No. 5,166,057 and in co-pending application Serial No. 08/252,508 filed June 1, 1994

(allowed), each of which is incorporated by reference in its entirety herein; i.e., so that the engineered viral RNA species directs the production of both the viral protein and the TAA as independent polypeptides.

5           Attenuated strains of influenza may be used as the "parental" strain to generate the influenza recombinants. Alternatively, reverse genetics can be used to engineer both the attenuation characteristics as well as the TAA or TAA epitope into the recombinant influenza viruses of the  
10 invention.

          In one embodiment, reverse genetics methods can be used to construct an influenza A virus transfectant that encodes a fragment or portion of a TAA, e.g., MART-1 or gp100 (melanoma TAAs). More preferably, sequences encoding such  
15 epitopes or fragments thereof are nested within an open reading frame, e.g., the hemagglutinin (HA) or neuraminidase (NA) open reading frames.

          In another embodiment, an independent minigene encoding a fragment or portion of an epitope, e.g., a  
20 minigene encoding a TAA or fragment thereof, is preceded by an endoplasmic reticulum insertion signal sequence, placed in a bicistronic arrangement in the NA RNA segment of the recombinant influenza A virus. Preferably, a transfectant expressing such a minigene mediates the presentation of the  
25 epitope to an anti-epitope CTL clone, and elicits specific cytolytic responses in vivo. Most preferably, such a transfectant, when administered in a vaccine formulation, mediates the regression of a tumor, metastasis, or neoplastic growth.

30

## 5.2. VACCINE FORMULATIONS USING THE RECOMBINANT VIRUSES

          The recombinant influenza viruses can be formulated as immunogenic compositions, which may be referred to herein as vaccines.

35           Either a live recombinant viral vaccine or an inactivated recombinant viral vaccine can be formulated. A live vaccine may be preferred because multiplication in the



rounds of replication. Such defective viruses can be produced by co-transfecting reconstituted RNPs lacking a specific gene(s) into cell lines which permanently express this gene(s). Viruses lacking an essential gene(s) will be replicated in these cell lines but when administered to the human host will not be able to complete a round of replication. Such preparations may transcribe and translate — in this abortive cycle — a sufficient number of genes to induce an immune response. Alternatively, larger quantities of the strains could be administered, so that these preparations serve as inactivated (killed) virus, vaccines. For inactivated vaccines, it is preferred that the heterologous gene product be expressed as a viral component, so that the gene product is associated with the virion. The advantage of such preparations is that they contain native proteins and do not undergo inactivation by treatment with formalin or other agents used in the manufacturing of killed virus vaccines.

In another embodiment of this aspect of the invention, inactivated vaccine formulations may be prepared using conventional techniques to "kill" the recombinant viruses. Inactivated vaccines are "dead" in the sense that their infectivity has been destroyed. Ideally, the infectivity of the virus is destroyed without affecting its immunogenicity. In order to prepare inactivated vaccines, the recombinant virus may be grown in cell culture or in the allantois of the chick embryo, purified by zonal ultracentrifugation, inactivated by formaldehyde or  $\beta$ -propiolactone, and pooled. The resulting vaccine is usually inoculated intramuscularly.

Inactivated viruses may be formulated with a suitable adjuvant in order to enhance the immunological response. Such adjuvants may include but are not limited to mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols, polyanions; peptides; oil emulsions; and potentially useful human adjuvants such as BCG and Corynebacterium parvum.

### 5.3. METHODS OF TREATMENT AND/OR VACCINATION

The recombinant influenza viruses of the invention can be used to treat tumor-bearing mammals, including humans, to generate an immune response against the tumor cells leading to tumor regression in vivo. The "vaccines" of the invention can be used either alone or in combination with other therapeutic regimens, including but not limited to chemotherapy, radiation therapy, surgery, bone marrow transplantation, etc. for the treatment of tumors. For example, surgical or radiation techniques could be used to debulk the tumor mass, after which, the vaccine formulations of the invention can be administered to ensure the regression and prevent the progression of remaining tumor masses or micrometastases in the body. Alternatively, administration of the "vaccine" can precede such surgical, radiation or chemotherapeutic treatment.

Alternatively, the recombinant viruses of the invention can be used to immunize or "vaccinate" tumor-free subjects to prevent tumor formation. With the advent of genetic testing, it is now possible to predict a subject's predisposition for cancers. Such subjects, therefore, may be immunized using a recombinant influenza virus expressing an appropriate tumor-associated antigen.

Many methods may be used to introduce the vaccine formulations described above into a patient. These include, but are not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, transdermal, epidural, pulmonary, gastric, intestinal, rectal, vaginal, or urethral routes. When the method of treatment uses a live recombinant influenza vaccine formulation of the invention, it may be preferable to introduce the formulation via the natural route of infection of the influenza virus, i.e., through a mucosal membrane or surface, such as an oral, nasal, gastric, intestinal, rectal, vaginal or urethral route. To induce a CTL response, the mucosal route of administration may be through an oral or nasal membrane. Alternatively, an intramuscular or

intraperitoneal route of administration may be used. Preferably, a dose of  $10^6$  -  $10^7$  PFU (plaque forming units) of cold adapted recombinant influenza virus is given to a human patient.

- 5           The ability of influenza virus to induce a vigorous secretory and cellular immune response may be used advantageously. For example, infection of the respiratory tract by recombinant influenza viruses may induce a strong secretory immune response in a particular tissue or organ  
10 system, for example, the urogenital system.

- Where subsequent or booster doses are required, a different serotype of influenza can be selected as the parental virus used to generate the recombinant. Alternatively, another virus such as vaccinia, or a subunit  
15 preparation can be used to boost. Immunization and/or cancer immunotherapy may be accomplished using a combined immunization regimen, e.g., immunization with a recombinant influenza viral vaccine of the invention and a boost of a recombinant vaccinia viral vaccine. In such an embodiment, a  
20 strong secondary  $CD8^+$  T cell response is induced after priming and boosting with different viruses expressing the same epitope (for such methods of immunization and boosting, see, e.g., Murata et al., Cellular Immunol. 173:96-107). For example, a patient is first primed with a vaccine formulation  
25 of the invention comprising a recombinant influenza virus expressing an epitope, e.g., a selected TAA or fragment thereof. The patient is then boosted, e.g., 21 days later, with a vaccine formulation comprising a recombinant vaccinia virus expressing the same epitope. Such priming followed by  
30 boosting induces a strong secondary  $CD8^+$  T cell response. Such a priming and boosting immunization regimen is preferably used to treat a patient with a tumor, metastasis or neoplastic growth expressing the selected TAA.

- In yet another embodiment, the recombinant  
35 influenza viruses can be used as a booster immunization subsequent to a primary immunization with inactivated tumor cells, a subunit vaccine containing the TAA or its epitope,



or another recombinant viral vaccine, such as vaccinia or adenovirus.

In an alternate embodiment, recombinant influenza virus encoding a particular TAA, epitope or fragment thereof  
5 may be used in adoptive immunotherapeutic methods for the activation of T lymphocytes that are histocompatible with the patient and specific for the TAA (for methods of adoptive immunotherapy, see, e.g., Rosenberg, U.S. Patent No. 4,690,915, issued September 1, 1987; Zarling, et al., U.S.  
10 Patent No. 5,081,029, issued January 14, 1992). Such T lymphocytes may be isolated from the patient or a histocompatible donor. The T lymphocytes are activated in vitro by exposure to the recombinant influenza virus of the invention. Activated T lymphocytes are expanded and  
15 inoculated into the patient in order to transfer T cell immunity directed against the TAA epitope.

6. EXAMPLE: TRANSFECTANT INFLUENZA A VIRUSES  
AS EFFECTIVE AND SAFE RECOMBINANT IMMUNOGENS  
IN THE TREATMENT OF CANCER

20 In the following example, reverse genetic methods were used to construct three different influenza A virus transfectants that encoded an L<sup>d</sup>-restricted, nine amino acid long fragment of  $\beta$ -galactosidase (corresponding to residues  
25 876-884). Sequences encoding this epitope were nested within the hemagglutinin (HA) or neuraminidase (NA) open reading frames. Alternatively, an independent  $\beta$ -galactosidase ( $\beta$ -gal) minigene, preceded by an endoplasmic reticulum insertion signal sequence, was placed in a bicistronic  
30 arrangement in the NA RNA segment of the virus. All three transfectants mediated the presentation of the epitope to an anti- $\beta$ -gal CTL clone. Furthermore, each of the three transfectant viruses expressing the  $\beta$ -gal fragment elicited specific cytolytic responses in vivo. Most importantly,  
35 these transfectants mediated the regression of established murine pulmonary metastases.

The following example also demonstrates the efficacy of transfectant influenza viruses expressing a TAA to clear tumors in a murine cancer model. The experimental murine tumor used, CT26, was transfected with the lacZ gene, which encodes the enzyme  $\beta$ -galactosidase ( $\beta$ -gal). Hence  $\beta$ -gal was used in this system as the model TAA. Transfectant influenza viruses were engineered that expressed a CTL epitope from the model  $\beta$ -gal antigen. Then, the ability of these viruses to induce a therapeutic cellular immune response in mice bearing tumors expressing  $\beta$ -gal was determined. The results demonstrate that influenza virus vectors may be used in cancer immunotherapy.

## 6.1. MATERIALS AND METHODS

### 6.1.1. ANIMALS AND CELL LINES

Six- to eight-week old female BALB/C (H-2<sup>d</sup>) mice were obtained from Frederick Cancer Research Center (Frederick, MD). CT26 is an N-nitroso-N-methylurethane induced BALB/C (H-2<sup>d</sup>) undifferentiated colon carcinoma. The cloning of this tumor cell line to produce CT26.WT and the subsequent transduction with lacZ and subcloning to generate CT-26.CL25 which stably expresses  $\beta$ -gal, has been described previously (Wang, et al., 1995, J. Immunol. 154:4685-4692).

These cell lines were maintained in RPMI 1640, 10% heat inactivated FCS (Biofluids, Rockville, MD), 0.03% L-glutamine, 100  $\mu$ g/m, streptomycin, 100  $\mu$ g/ml penicillin and 50  $\mu$ g/ml gentamicin sulfate (NIH Media Center). In addition, 400 or 800  $\mu$ g/ml G418 (GIBCO, Grand Island, N.Y.) was added to the maintenance media of the CT26.CL25 cells. Madin-Darby bovine kidney (MDBK) cells were used for growing wild-type influenza A/WSN/33 virus and for rescuing and growing transfectant influenza viruses. MDBK cells were maintained in reinforced minimal essential medium containing 10% heat inactivated FCS (GIBCO, Grand Island, N.Y.)

35

6.1.2. CONSTRUCTION AND CHARACTERIZATION OF  
TRANSFECTANT INFLUENZA A VIRUSES (FIG. 1)

The construction of the transfectant influenza viruses BIP-NA, MNA and ELDKWAS which were used in control experiments has been described (Garcia-Sastre, et al., 1994, J. Virol. 68:6254-6261; Rodrigues, et al., 1994, J. Immunol. 153:4636-4648; Muster, et al., 1994, J. Virol. 68:4031-4034). Transfectant viruses which express the L<sup>d</sup>-restricted  $\beta$ -gal epitope TPHPARIGL were obtained by RNP-transfection as previously described (Garcia-Sastre and Palese, 1993, Annu. Rev. Microbiol. 47:765-790). These viruses contain one RNA segment which is derived from genetically engineered plasmid cDNA encoding the neuraminidase (NA) or hemagglutinin (HA) genes of influenza A/WSN/33 virus. One virus, called MINIGAL, encodes the amino acid sequence MRYMILGLLALAAVCSAATPHPARIGL from a minicistron followed by a mammalian internal ribosomal entry site (IRES) element just upstream of the NA open reading frame. Amino acid residues in front of the  $\beta$ -gal epitope TPHPARIGL are derived from the leader peptide of the E3/19K protein (Restifo, et al., 1995, J. Immunol. 154:4414-4422). A control virus, BIPNA, contains the same IRES sequences upstream of the NA open reading frame but lacks the  $\beta$ -gal minicistron (Garcia-Sastre, et al., 1994, J. Virol. 68:6254-6261). The second transfectant virus, NAGAL, encodes for the amino acid sequence TPHPARIGL inserted in the stalk region of the NA protein. The third transfectant influenza virus, BHAGAL, encodes the same  $\beta$ -gal epitope inserted into the antigenic site B of the viral HA protein. MNA and ELDKWAS viruses, which contain irrelevant epitope insertions in the same context as NAGAL and BHAGAL viruses, respectively, were used as controls. Transfectant viruses were plaque purified three times in MDBK cells and their identities were subsequently confirmed by RT-PCR and sequencing of gene regions containing the engineered foreign sequences (Garcia-Sastre, et al., 1994, J. Virol. 68:6254-6261).

### 6.1.3. PEPTIDES

The synthetic peptide TPHPARIGL was synthesized by Peptide Technologies (Washington D.C.) to a purity of greater than 99% as assessed by HPLC and amino acid analysis. This peptide represents the naturally processed H-2 L<sup>d</sup> restricted epitope spanning amino acids 876-884 of  $\beta$ -gal.

### 6.1.4. <sup>51</sup>CHROMIUM RELEASE ASSAYS

Six-hour <sup>51</sup>Cr release assays were performed as previously described. Briefly, 2 x 10<sup>6</sup> target cells were incubated with 200mCi Na<sup>51</sup>CrO<sub>4</sub>(<sup>51</sup>Cr) for ninety minutes. Peptide pulsed CT26.WT cells were incubated with 1  $\mu$ g/ml of synthetic peptide during labeling. Target cells were then mixed with effector cells for six hours at the effector to target (E:T) ratios indicated. The amount of <sup>51</sup>Cr released was determined by  $\gamma$ -counting and the percentage of specific lysis was calculated from triplicate samples as follows:  
[(experimental cpm - spontaneous cpm)/maximal cpm - spontaneous cpm] x 100.

### 6.1.5. IN VITRO STIMULATION OF $\beta$ -GAL-SPECIFIC CYTOTOXIC T CELLS

10<sup>5</sup> CT26.WT cells/well in 96 well, U-bottom plates (Costar,) were incubated in complete medium (RPMI, 0.1% BSA, 30mM HEPES at Ph 6.8) and infected with the influenza viruses shown at a multiplicity of infection (MOI) of 20 for 3 hours. CTL<sub>x</sub>, which are specific for the  $\beta$ -gal epitope were then added at an E:T of 1. After 24 hours of coincubation, supernatants were harvested and assayed for GM-CSF.

### 6.1.6. IN VIVO EXPERIMENTS

Active treatment studies involved BALB/c mice inoculated intravenously with 5 x 10<sup>5</sup> CT2.CL25 cells. Three days later, mice were randomized, then inoculated with 10<sup>6</sup> PFU of the indicated transfectant or wild-type influenza virus. Twelve days after tumor injection, mice were ear tagged,

randomized again, and sacrificed. Lung metastases were enumerated in a blinded fashion by an investigator with no knowledge of the experimental groups.

5

#### 6.1.7. STATISTICAL ANALYSIS

Data concerning the number of lung metastases do not follow a nominal distribution (since all lungs that contain > 250 metastases were deemed too numerous to count) and thus were analyzed using the non-parametric two tailed  
10 Kruskal-Wallis test. All statistical values expressed are  $P_2$  values.

#### 6.2. RESULTS

##### 6.2.1. RESCUE OF TRANSFECTANT INFLUENZA A 15 VIRUSES ENCODING A T CELL EPITOPE FROM $\beta$ -GALACTOSIDASE

Recombinant viruses encoding a single CD8<sup>+</sup> T cell antigenic determinant of 8-10 amino acids in length can mediate the regression of experimental tumors (Irvine, et  
20 al., 1995, J. Immunol. 154:4651-4657; McCabe, et al., 1995, Cancer Res. 55:1741-1747; Restifo, 1996, Curr. Opin. Immunol. 8:658-663). Thus transfectant influenza A viruses were constructed that expressed the epitope TPHPARIGL. This determinant corresponds to amino acids 876-884 in the intact  
25  $\beta$ -gal protein and is presented by the MHC class I L<sup>d</sup>-molecule on the surface of the CT26.CL25 mouse tumor cells (Wang, et al., 1995, J. Immunol. 154:4685-4692).

Three different influenza A virus transfectants were generated (Fig. 1). The first transfectant virus,  
30 called MINIGAL, contained a minigene in a bicistronic arrangement within the NA-specific viral RNA segment. mRNA derived from this segment uses a mammalian IRES placed downstream of the minigene and upstream of the NA gene to achieve translation of the NA protein. In addition, the  
35 minigene is translated following the usual cap-dependent initiation of translation in eukaryotic cells. In this transfectant virus, the minigene was engineered to encode the

E3/19K leader sequence at the N-terminus of the  $\beta$ -gal epitope  
TPHPARIGL. The ER-insertion signal sequence has been found,  
in some cases, to greatly augment the immunogenicity of the  
encoded epitope (Restifo, et al., 1995, J. Immunol. 154:4414-  
5 4422). The control virus for this construct, designated  
BIPNA virus, employs the same IRES upstream of NA open  
reading frame but does not contain the  $\beta$ -gal epitope minigene  
(Garcia-Sastre, et al., 1994, J. Virol. 68:6254-6261). The  
second virus, NAGAL, encodes for the amino acid sequence  
10 TPHPARIGL inserted in the stalk region of the NA protein.  
The control for this construct is the MNA transfectant virus,  
which contains the irrelevant peptide SYVPSAEQI inserted into  
the NA stalk. This sequence is derived from the CS protein  
of P. yoelii (Rodrigues, et al., 1994, J. Immunol. 153:4636-  
15 4648). The third virus called BHAGAL encodes the  $\beta$ -gal  
epitope inserted into the antigenic site B of the HA protein.  
The control for this virus is designated ELDKWAS virus, which  
contains the gp41 HIV-derived sequence ELDKWAS inserted into  
the same domain of the HA (Muster, et al, 1995, J. Virol.  
20 69:6678-6686).

Transfectant viruses MINIGAL, NAGAL and BHAGAL were  
rescued following RNP transfections into helper influenza  
virus infected cells. Sequence analysis of the rescued  
viruses confirmed the presence of the foreign  $\beta$ -gal-derived  
25 sequences. Viral titers obtained in MDBK cells for the  
transfectant viruses expressing the  $\beta$ -gal-epitope were  
comparable to the control transfectant viruses BIPNA, MNA and  
ELDKWAS and slightly lower (approximately one log) than wild-  
type influenza A/WSN/33 virus.

30

6.2.2. TRANSFECTANT INFLUENZA VIRUS-INFECTED  
CELLS ARE ABLE TO SPECIFICALLY PRESENT  
THE  $\beta$ -GAL-EPI TOPE TO CD8<sup>+</sup> T CELLS

To ascertain if the  $\beta$ -gal-epitope expressed by the  
35 transfectant influenza viruses could be processed and  
presented in the context of MHC class I molecules, CT26.WT  
tumor cells were infected with the different transfectant

influenza A viruses encoding the  $\beta$ -gal epitope TPHPARIGL, or the control viruses. Infected cells were then co-incubated for 24 hours with a CD8<sup>+</sup> T lymphocyte clone specific for this epitope. Supernatants were then assayed for GM-CSF, and the results are shown in Fig. 2. Cells that were infected with MINIGAL, NAGAL and BHAGAL viruses elicited specific release of GM-CSF. Neither control transfectant virus- or wild-type virus-infected cells were recognized by the  $\beta$ -gal-specific CTLs. Thus, the transfectant influenza A viruses were found to mediate the expression of the L<sup>d</sup>-restricted  $\beta$ -gal epitope in forms that could be processed and presented at the surface of infected cells.

6.2.3. TRANSFECTANT INFLUENZA A VIRUSES  
ELICIT A  $\beta$ -GAL SPECIFIC CYTOLYTIC  
RESPONSE IN MICE

Cytolytic responses mediated by CD8<sup>+</sup> T lymphocytes specific for TAA play an important role in the regression of established tumor in both mouse and man (Greenberg, 1991, Adv. Immunol. 49:281-355; Rao, *et al.*, 1996, J. Immunol. 156:3357-3365; Rosenberg, 1994, J. Natl. Cancer. Inst. 86:1159-1166). To evaluate the function of transfectant influenza A viruses in the priming of  $\beta$ -gal-specific cytotoxic responses *in vivo*, we immunized mice with the panel of influenza A viruses. Three weeks later, splenocytes from immunized mice were cultured in the presence of the L<sup>d</sup>-restricted  $\beta$ -gal<sub>876-884</sub> peptide for 6 days and subsequently tested in a microcytotoxicity assay. Cultured splenocytes from mice immunized with the three transfectant influenza A viruses expressing the  $\beta$ -gal epitope (MINIGAL, NAGAL and BHAGAL viruses) were capable of specific recognition of CT26.CL25 cells or of CT26.WT cells pulsed with synthetic peptide (Figure 3). No specific recognition was elicited by wild-type virus, or by the control transfectant viruses.

6.2.4. TREATMENT OF TUMORS ESTABLISHED FOR  
THREE DAYS BY VACCINATION WITH  
TRANSFECTANT INFLUENZA A VIRUSES

Specific cytolytic responses were elicited in mice  
5 by the transfectant influenza A viruses expressing the  
 $\beta$ -gal<sub>876-884</sub> peptide. To evaluate whether these responses had any  
impact on the growth of tumor cells, we immunized mice  
bearing CT26.CL25 tumors established for three days with our  
panel of recombinant immunogens. As shown in Figure 4,  
10 treatment of mice with MINIGAL, NAGAL or BHAGAL viruses  
resulted in a statistically significant reduction of the  
number of lung metastases. In some instances, treated mice  
did not show any macroscopic evidence of lung tumors by day  
12.

15

6.3. DISCUSSION

The results demonstrate that transfectant influenza  
A viruses expressing a single tumor antigen determinant can  
mediate the regression of an experimental murine cancer  
20 established for three days, thereby inducing a therapeutic  
antitumor response in mice. In clinical cancer trials at the  
National Cancer Institute and elsewhere, the recombinant  
viral vectors that are currently in use include E1-deleted  
adenoviruses and two recombinant poxviruses: vaccinia and  
25 fowlpox viruses. These virus vectors have been engineered to  
express selected human TAA. It has been shown previously  
that adenovirus- and poxvirus-based vectors are also able to  
induce tumor clearance in experimental murine cancer models  
(Wang, et al., 1995, J. Immunol. 154:4685-4692; McCabe, et  
30 al., 1995, Cancer Res. 55:1741-1747; Chen, et al., 1996, J.  
Immunol. 156:224-231). However, most cancer patients  
encountered in clinical settings appear to have high  
circulating levels of neutralizing titers to the adenovirus  
vectors commonly used. The same is true for vaccinia  
35 viruses, where the vast majority of patients have received  
the virus as children during the effort by the World-Health  
Organization's effort to eradicate smallpox world-wide.



Indeed, many patients can also have neutralizing antibodies to many strains of the influenza A virus. However, humans are susceptible to repeated bouts of influenza-mediated upper respiratory symptoms because influenza viruses can almost  
5 endlessly change the antigenic characteristics of their viral coat.

Epidemiologists around the world attempt to predict which coat will be the most evolutionarily successful in any given year. Tumor immunotherapists must do exactly the  
10 opposite, that is, study their target cancer-bearing cohort(s) of patients, then choose a viral coat that has not penetrated that population either because of unsuccessful penetration or because the cohort of patients to receive therapeutic immunization was not yet born when penetration  
15 occurred. The latter case would involve, for example, the use of an influenza virus vector bearing a viral coat from 1934 and expressing a selected TAA to treat a population that was under age 60.

In the case of fowlpox virus vectors, there are no  
20 problems of preexisting immunity against the vector. However, poxviruses are highly complex viruses that express many different immunosuppressor proteins (Moss, 1996, in Virology, Fields, et al., eds., Philadelphia, Lippincott-Raven, pp. 2637-2671). This and the nonreplicative nature of  
25 the vector in humans might contribute to the induction of suboptimal immune responses by the vector against their expressed TAA. Furthermore, repeated administrations of the same vector to boost the cellular immune responses are usually not successful. Thus, the first administration of  
30 the vector results in the induction of neutralizing antibodies against the vector that hamper its ability to subsequently reinfect the same patient. This could be circumvented by combined immunizations with two different vectors sharing the same TAA. A very promising protocol  
35 involves the use of an influenza virus vector to prime an immune response against the expressed TAA, followed by a poxvirus vector expressing the same TAA for boosting. It has

been shown that this protocol of immunization is extremely efficient in mice for the induction of powerful specific CTL responses against foreign malarial antigens which are expressed by the vectors (Murata, et al., 1996, Cell.

5 Immunol. 173:96-107).

Another advantage of the use of influenza virus vectors to express TAA is their antigenic simplicity. Influenza A virus encodes only ten proteins, as compared to the 185 open reading frames of vaccinia virus. Thus, the  
10 proportion of the expressed desired antigen among other viral antigens is higher for influenza virus than for adenovirus or poxvirus vectors. We have engineered three influenza virus vectors expressing the same  $\beta$ -gal epitope in different contexts. Among these three transfectant viruses, BHAGAL  
15 virus, which express the  $\beta$ -gal epitope in the context of the HA gene, is expected to express higher levels of the epitope than the other two viruses, MINIGAL and NAGAL, which express the  $\beta$ -gal-epitope in the context of the NA gene. Thus, the HA gene expression levels are approximately 5-10 times higher  
20 than the NA gene expression levels. On the other hand, the MINIGAL virus might more efficiently deliver the epitope to MHC class I molecules due to the use of a leader sequence in front of the epitope. Finally, one might also expect differences in the efficiency of processing of the  $\beta$ -gal  
25 epitope according to the different flanking amino acid sequences that are present in the three viral vectors. However, all of the three viruses were able to induce a therapeutic immune response against tumors expressing  $\beta$ -gal in mice. Future experiments are needed to precisely compare  
30 the levels of CTL activation induced by the virus vectors against the  $\beta$ -gal epitope.

Safety is one major concern in the use of influenza virus vectors in humans. The use of nontransmissible, attenuated cold-adapted influenza virus vectors provides a  
35 means to safely administer the vector to humans. These cold-adapted strains have been obtained by the propagation of the virus at progressively lower temperatures, resulting in the

selection and accumulation of mutations responsible for both cold-adaptation and attenuation. Alternatively, the administration of transfectant influenza viruses by routes different from the respiratory route can also provide a safe way to use these vectors in humans. Thus, influenza A viruses are able to productively infect the respiratory epithelium, but they do cause neither viral shedding nor disease when administered by non respiratory routes, such as intravenously, intraperitoneally, intramuscularly or subcutaneously, for example. However, these routes of administration are equally effective as the intranasal route in eliciting a cellular immune response against expressed antigens by the influenza virus vectors (Murata, et al., 1996, Cell. Immunol. 173:96-107). In fact, the mouse immunizations described in this communication were done intraperitoneally and they resulted in both an induction of CTLs against the model TAA and in tumor regression.

The capacity of influenza A viruses to infect dendritic cells and to express their genes at high levels is an important one. Dendritic cells are potent activators of T lymphocyte-dependent immune responses. They have a remarkably high density of both MHC class I and class II on their surfaces together with costimulatory molecules like B7-1/CD80 and B7-2/CD86, as well as other T cell activating ligands including ICAM-1/CD54. Dendritic cells infected with influenza viruses expressing TAA ex vivo, then reinfused, could be used to activate anti-tumor T cells in vivo. (In fact, the elicitation of potent anti-tumor immunity described in this example might be mediated by the infection of dendritic cells in vivo). One alternative scenario involves the use of dendritic cells infected with influenza viruses encoding TAA to generate in vitro activated anti-tumor T cells that can subsequently be adoptively transferred. A similar strategy has been used with considerable success by Greenberg and colleagues to generate anti-CMV reactivities using recombinant vaccinia-virus infected dendritic cells. However, vaccinia viruses are about 20 fold more

antigenically complex and they are thus much more likely to elicit irrelevant reactivities than an influenza A virus vector.

These results support the use of influenza virus  
5 vectors in cancer therapy. In our murine cancer system, the tumorigenic properties of the cell line CT26.CL25 remain unchanged upon expression of the model TAA  $\beta$ -gal. This resembles the situation in most human tumors, which express TAA but are not able to induce an immune response against  
10 their TAA. Hence the results suggest that influenza viruses expressing identified human TAA will be efficacious in the treatment of human tumors. The development of influenza virus vectors expressing human TAA will advance the field of cancer therapy towards new therapeutic strategies to treat  
15 human tumors and prolong survival.

The present invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and any constructs, viruses or enzymes which are functionally  
20 equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to  
25 fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

30

35

WHAT IS CLAIMED IS:

1. A recombinant influenza virus the genome of which contains a region encoding a tumor-associated antigen.  
5
2. The recombinant influenza virus of Claim 1 in which the region is contained within a structural gene of influenza virus.
- 10 3. The recombinant influenza virus of Claim 2 in which the structural gene is HA, NA, NP or M.
4. The recombinant influenza virus of Claim 1 in which the region encoding the tumor-associated antigen is in  
15 a bicistronic arrangement with an influenza virus gene.
5. The recombinant influenza virus of Claim 1 which is an attenuated virus.
- 20 6. An immunogenic formulation comprising an effective amount of the recombinant influenza virus of Claim 1, 2, 3, 4 or 5 and a pharmaceutically acceptable carrier.
7. The immunogenic formulation of Claim 6 in which  
25 the recombinant influenza virus is a live virus.
8. The immunogenic formulation of Claim 6 in which the recombinant influenza virus is a killed virus.
- 30 9. A vaccine formulation comprising an effective amount of the recombinant influenza virus of Claim 1, 2, 3, 4 or 5 and a pharmaceutically acceptable carrier.
10. The vaccine formulation of Claim 9 in which  
35 the recombinant influenza virus is a live virus.

11. The vaccine formulation of Claim 9 in which the recombinant influenza virus is a killed virus.

12. A method for immunization of a tumor-bearing  
5 patient, comprising administering the immunogenic formulation of Claim 6 to the patient bearing a tumor which expresses the tumor-associated antigen.

13. The method of Claim 12 in which the  
10 immunogenic formulation comprises a live recombinant influenza virus.

14. The method of Claim 12 in which the immunogenic formulation comprises a killed recombinant  
15 influenza virus.

15. The method of Claim 12 further comprising the subsequent administration of a booster preparation.

16. The method of Claim 12 in which the booster  
20 preparation is an immunogenic formulation comprising an influenza virus having a serotype that differs from that of the recombinant influenza virus used in the initial immunization.

17. The method of Claim 12 in which the booster  
25 preparation is an immunogenic formulation comprising a recombinant virus that differs from influenza virus.

18. The method of Claim 17 in which the  
30 recombinant virus is a vaccinia virus.

19. A method for immunizing a tumor-free patient,  
35 comprising administering the immunogenic formulation of Claim 6 to the patient.

ABSTRACT

The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these  
5 viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in  
10 combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.

15

20

25

30

35




Fig. 1








Fig. 2





# DECLARATION AND POWER OF ATTORNEY

Below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

## RECOMBINANT INFLUENZA VIRUSES EXPRESSING TUMOR-ASSOCIATED ANTIGENS AS ANTITUMOR AGENTS

and for which a patent application:

- ☐ is attached hereto and includes amendment(s) filed on \_\_\_\_\_ (if applicable)  
☐ was filed in the United States on \_\_\_\_\_ as Application No. \_\_\_\_\_ (for declaration not accompanying application)

with amendment(s) filed on \_\_\_\_\_ (if applicable)

- ☐ was filed as PCT international Application No. \_\_\_\_\_ on \_\_\_\_\_ and was amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/045,176	April 30, 1997

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Isaac Jarkovsky (Reg. No. 22713), Joseph V. Colaiaanni (Reg. No. 20019), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), Ann L. Gisolfi (Reg. No. 31956), Mark A. Farley (Reg. No. 33170), and James G. Markey (Reg. No. 31636), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

<b>SEND CORRESPONDENCE TO:</b>		<b>PENNIE &amp; EDMONDS LLP</b> 1155 AVENUE OF THE AMERICAS NEW YORK, N.Y. 10036-2711		<b>DIRECT TELEPHONE CALLS TO:</b> <b>PENNIE &amp; EDMONDS LLP DOCKETING</b> (212) 790-2803	
201	FULL NAME OF INVENTOR	LAST NAME Palese	FIRST NAME Peter	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY Leonia	STATE OR FOREIGN COUNTRY New Jersey	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET 414 Highwood Avenue	CITY Leonia	STATE OR COUNTRY New Jersey	ZIP CODE 07605
202	FULL NAME OF INVENTOR	LAST NAME García-Sastre	FIRST NAME Adolfo	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY New York	STATE OR FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET 16 East 96th Street, Apt. 3G	CITY New York	STATE OR COUNTRY NY	ZIP CODE 10128
203	FULL NAME OF INVENTOR	LAST NAME Rosenberg	FIRST NAME Steven	MIDDLE NAME A.	
	RESIDENCE & CITIZENSHIP	CITY Bethesda	STATE OR FOREIGN COUNTRY Maryland	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
204	FULL NAME OF INVENTOR	LAST NAME Restifo	FIRST NAME Nicholas	MIDDLE NAME P.	
	RESIDENCE & CITIZENSHIP	CITY Washington, D.C.	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203
DATE	DATE	DATE
SIGNATURE OF INVENTOR 204	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE	DATE	DATE